Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma

Next Previous
X
Search
Trial Profile

Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoposide-toniribate (Primary)
  • Indications Biliary cancer; Carcinoma; Non-small cell lung cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms PIITCAP
  • Sponsors CellAct Pharma

    • Most Recent Events

    • 22 Feb 2019 Results presented in an Imbrium Therapeutics media release.
    • 22 Feb 2019 According to an Imbrium Therapeutics media release, the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to etoposide toniribate, for the treatment of relapsed refractory biliary tract cancer. Encouraging data in Phase 2 trials were key in securing the ODD.
    • 19 Jan 2019 Results from biliary tract cancer patients (n=22) presented at the 2019 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top